Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database

被引：0
|
作者：
Stephanie H. Read
Nadia Quignot
Raissa Kapso-Kapnang
Erin Comerford
Ying Zheng
Corona Gainford
Medha Sasane
Anne-Lise Vataire
Laure Delzongle
Francois-Clement Bidard
机构：
[1] Certara UK Limited,Department of Medical Oncology
[2] Certara France,undefined
[3] Sanofi,undefined
[4] Sanofi,undefined
[5] Institut Curie,undefined
[6] Université Versailles Saint-Quentin,undefined
[7] Université Paris-Saclay,undefined
来源：
Breast Cancer Research and Treatment | 2024年 / 204卷
关键词：
Hormone receptor negative; Metastatic breast cancer; Endocrine therapy; Cyclin-dependent kinase 4/6 inhibitor; Real-world evidence; SNDS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：579 / 588
页数：9
相关论文
共 50 条
  • [1] Treatment patterns of patients with HR+/HER2-metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database
    Read, Stephanie H.
    Quignot, Nadia
    Kapso-Kapnang, Raissa
    Comerford, Erin
    Zheng, Ying
    Gainford, Corona
    Sasane, Medha
    Vataire, Anne-Lise
    Delzongle, Laure
    Bidard, Francois-Clement
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (03) : 579 - 588
  • [2] TREATMENT PATTERNS FOLLOWING FIRST LINE CDK4/6 INHIBITOR PROGRESSION IN HR+, HER2-METASTATIC BREAST CANCER
    Behan, E.
    Bansal, A.
    Veenstra, D.
    VALUE IN HEALTH, 2024, 27 (06) : S406 - S406
  • [3] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [4] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [5] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [6] CDK4/6 inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer
    Zhang, Jie
    Hao, Chunfang
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [7] MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
    Dickler, Maura N.
    Tolaney, Sara M.
    Rugo, Hope S.
    Cortes, Javier
    Dieras, Veronique
    Patt, Debra
    Wildiers, Hans
    Hudis, Clifford A.
    O'Shaughnessy, Joyce
    Zamora, Esther
    Yardley, Denise A.
    Frenzel, Martin
    Koustenis, Andrew
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5218 - 5224
  • [8] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [9] Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2- Metastatic Breast Cancer: A Podcast
    Dong, Brian
    Lusen, Rita
    Chick, Ella
    Kline, Lisa
    ONCOLOGY AND THERAPY, 2023, 11 (04) : 411 - 418
  • [10] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
12345